Jessica Hassel

52PUBLICATIONS

221CO-AUTHORS

Tumour immunologyMolecular targetsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Predictive and prognostic markersCardiovascular medicine and haematology not elsewhere classified

Get your video featured.

Publish with JoVE

Get your video featured.

Publish with JoVE

Publications (52)

Sort by Publication Date:

|Jun 25, 2026

Immune checkpoint inhibitor therapy after tumor-infiltrating lymphocytes in unresectable melanoma.

|Apr 27, 2026

Re-Exposure of a PD-1 Inhibitor After Previous Immune-Related Adverse Events.

|Apr 21, 2026

MONETTE: A Randomized Phase II Study of Ceralasertib plus Durvalumab or Ceralasertib Monotherapy in Patients with Advanced Melanoma Resistant to PD-(L)1 Inhibition.

|Mar 14, 2026

Mycophenolate Mofetil for Treatment of Ipilimumab-Induced Colitis in Patients with Metastatic Melanoma.

Christina Naoum, Julia K Winkler, Pawel Majenka

|Mar 05, 2026

Resistance to anti-PD-1 immunotherapy for stage III and IV melanoma: a global chart review study.

Elizabeth M Gaughan, Miso Kim, Ignacio Mendez

|Feb 27, 2026

COMBI-EU: Real-World Evidence on Adverse Event Management and Time on Therapy with Adjuvant Dabrafenib Plus Trametinib in Patients with BRAF V600-Mutant Melanoma.

Michael Weichenthal, Dirk Debus, Lisa Zimmer

Pageof 9

Frequent Collaborators

11 joint publications

Ralf Gutzmer

Christoffer Gebhardt

Dirk Schadendorf

Selma Ugurel

Jochen Utikal

Markus Vincent Heppt

Michael Weichenthal

Carola Berking

Friedegund Meier

Paolo A Ascierto

Frequent Collaborators

11 joint publications

Ralf Gutzmer

7 joint publications

Christoffer Gebhardt

7 joint publications

Dirk Schadendorf

6 joint publications

Selma Ugurel